⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VERA News
Vera Therapeutics, Inc. Class A Common Stock
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
globenewswire.com
VERA
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VERA
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
globenewswire.com
VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
VERA
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
globenewswire.com
VERA
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VERA